Research ArticleClinical Studies

Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan

NAOTAKA SHIMOZATO, TADASHI NAMISAKI, AKIHIRO OKANO, MASAYA OHANA, DAISUKE KINOSHITA, TOSHIHIKO KAWASAKI, YOSUKE AIHARA, TOSHIYA NAKATANI, HIROKI KINOSHITA, TATSUICHI ANN, KO SAITO, MOTOYUKI YOSHIDA and HITOSHI YOSHIJI
Anticancer Research January 2022, 42 (1) 173-183; DOI: https://doi.org/10.21873/anticanres.15471

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Flow chart showing patient enrolment in the study.

  • Figure 2.
    Figure 2.

    Kaplan–Meier analysis of progression-free survival in 142 patients treated with lenvatinib. Median progression-free survival was 176 days (95% confidence interval=134-234 days).

  • Figure 3.
    Figure 3.

    Kaplan–Meier analysis of progression-free survival in 142 patients with hepatocellular carcinoma treated with lenvatinib stratified by Child–Pugh score (A), tumour number (B), des-gamma-carboxy prothrombin (DCP) level (C), vascular invasion (D), extrahepatic metastasis (E) and adverse effects (F).

  • Figure 4.
    Figure 4.

    Kaplan–Meier analysis of progression-free survival in 142 patients with hepatocellular carcinoma treated with lenvatinib stratified by the REFLECT trial eligibility criteria (A), Child–Pugh grade (B), main portal trunk invasion (Vp4) (C) and prior tyrosine kinase inhibitor (TKI) therapy (D).

Tables

  • Table I.
  • Table II.
  • Table III.
  • Table IV.
  • Table V.
  • Table VI.
  • Table VII.
  • Table VIII.
  • Table IX.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan
NAOTAKA SHIMOZATO, TADASHI NAMISAKI, AKIHIRO OKANO, MASAYA OHANA, DAISUKE KINOSHITA, TOSHIHIKO KAWASAKI, YOSUKE AIHARA, TOSHIYA NAKATANI, HIROKI KINOSHITA, TATSUICHI ANN, KO SAITO, MOTOYUKI YOSHIDA, HITOSHI YOSHIJI
Anticancer Research Jan 2022, 42 (1) 173-183; DOI: 10.21873/anticanres.15471
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords